Article Hero

J&J quarterly earnings came ahead of forecast

Miguel A. Rodriguez
Miguel A. Rodriguez
27 enero 2021
Johnson & Johnson reported fourth-quarter figures that topped consensus

In Q4, JNJ had an adjusted EPS of $1.86, slightly higher than the $1.82 per share expected. At the same time, the company generated revenues of $22.48 billion, while the market was looking for $21.67 billion.

Much of its revenue came from the pharmaceutical business, which produces the COVID-19 vaccine. The division reported revenues of $12.26 billion, 16% higher than that reported in Q4 2019.

For the future, Johnson & Johnson expects an adjusted EPS between $9.40-$9.60, and sales to reach a high of $91.7 billion. Moreover, as early as next week, the company is expected to publish data from Phase III of its COVID-19 vaccine trial.

Both US officials and Wall Street are looking forward to the vaccine to receive FDA’s approval. #JNJ’s vaccine requires just one dose to be administrated, unlike Moderna’s and Pfizer’s, which requires two doses.

Following the news, Johnson & Johnson stock price gained 2% in today’s premarket session.

Stay updated with the latest earning reports with!







Miguel A. Rodriguez
Miguel A. Rodriguez

Miguel comenzó su destacada carrera profesional en reputadas instituciones financieras como el Banco Santander y el Banco Central-Hispano. Es autor de importantes libros sobre trading en el mercado de divisas.